As both JAK inhibitors and anti-TNF medications have outstanding efficacy in treating RA and anti-TNFs are the most common medications treating inflammatory bowel disease, including Crohn’s Disease [2], these therapies may target the inflammatory macrophages in severe COVID-19 lung during the phase involving cytokine release syndrome [43]. This evidence concerns the gene TNF and inflammatory bowel disease.